This Article Full Text Full Text (PDF) All Versions of this Article: 92/4/1305    most recent Author Manuscript (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grey, A. Articles by Reid, I. R. Search for Related Content PubMed PubMed Citation Articles by Grey, A. Articles by Reid, I. R. Related Collections Calcium and Bone Metabolism Diabetes and Insulin

The Peroxisome Proliferator-Activated Receptor- Agonist Rosiglitazone Decreases Bone Formation and Bone Mineral Density in Healthy Postmenopausal Women: A Randomized, Controlled Trial

Department of Medicine (A.G., M.B., G.G., D.W., A.H., I.R.R.), University of Auckland, and LabPlus (J.D.), Auckland City Hospital, 1020 Auckland, New Zealand

Address all correspondence and requests for reprints to: Dr. Andrew Grey, Department of Medicine, University of Auckland, Private Bag 92019, 1020 Auckland, New Zealand. E-mail: a.grey{at}auckland.ac.nz.

Context: Thiazolidinediones, which are peroxisome proliferator-activated receptor- agonists, are widely prescribed to patients with disorders characterized by insulin resistance. Preclinical studies suggest that peroxisome proliferator-activated receptor- signaling negatively regulates bone formation and bone density. Human data on the skeletal effects of thiazolidinediones are currently available only from observational studies.

Objective: The objective of the study was to determine whether rosiglitazone, a thiazolidinedione, inhibits bone formation.

Design: The study was a 14-wk randomized, double-blind, placebo-controlled trial.

Setting: The study was conducted in the general community.

Patients: Fifty healthy, postmenopausal women participated in the study.

Intervention: Intervention was rosiglitazone 8 mg/d.

Main Outcome Measures: The primary end point was biochemical markers of bone formation, and secondary end points were a bone resorption marker and bone mineral density.

Results: The osteoblast markers procollagen type I N-terminal propeptide and osteocalcin declined by 13% (P < 0.005 vs. placebo) and 10% (P = 0.04 vs. placebo), respectively, in the rosiglitazone group. These changes were evident by 4 wk and persisted for the duration of the study. There was no change in the serum ß-C-terminal telopeptide of type I collagen, a marker of bone resorption (P = 0.9 vs. placebo). Total hip bone density fell in the rosiglitazone group (mean change from baseline rosiglitazone –1.9%, placebo –0.2%; between-group difference 1.7%, 95% confidence interval 0.6–2.7, P < 0.01); lumbar spine bone density fell significantly from baseline values in the rosiglitazone group (P = 0.02 vs. baseline) but was not significantly different between groups (mean change from baseline rosiglitazone –1.2%, placebo –0.2%; between-group difference 1.0%, 95% confidence interval –0.2–2.3, P = 0.13).

Conclusions: Short-term therapy with rosiglitazone exerts detrimental skeletal effects by inhibiting bone formation. Skeletal end points should be included in future long-term studies of thiazolidinedione use.

This article has been cited by other articles:

				D. Glintborg, M. Andersen, C. Hagen, L. Heickendorff, and A. P. Hermann Association of Pioglitazone Treatment with Decreased Bone Mineral Density in Obese Premenopausal Patients with Polycystic Ovary Syndrome: A Randomized, Placebo-Controlled Trial J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1696 - 1701. [Abstract] [Full Text] [PDF]

				S. E. Kahn, B. Zinman, J. M. Lachin, S. M. Haffner, W. H. Herman, R. R. Holman, B. G. Kravitz, D. Yu, M. A. Heise, R. P. Aftring, et al. Rosiglitazone-Associated Fractures in Type 2 Diabetes: An analysis from A Diabetes Outcome Progression Trial (ADOPT) Diabetes Care, May 1, 2008; 31(5): 845 - 851. [Abstract] [Full Text] [PDF]

				J. A. Cauley and K. E. Ensrud Considering Competing Risks . . . Not All Black and White Arch Intern Med, April 28, 2008; 168(8): 793 - 795. [Full Text] [PDF]

				C. Meier, M. E. Kraenzlin, M. Bodmer, S. S. Jick, H. Jick, and C. R. Meier Use of Thiazolidinediones and Fracture Risk Arch Intern Med, April 28, 2008; 168(8): 820 - 825. [Abstract] [Full Text] [PDF]

				A. B. Grey Skeletal Toxicity of Thiazolidinediones Ann Intern Med, April 1, 2008; 148(7): 563 - 563. [Full Text] [PDF]

				M. Monami, B. Cresci, A. Colombini, L. Pala, D. Balzi, F. Gori, V. Chiasserini, N. Marchionni, C. M. Rotella, and E. Mannucci Bone Fractures and Hypoglycemic Treatment in Type 2 Diabetic Patients: A case-control study Diabetes Care, February 1, 2008; 31(2): 199 - 203. [Abstract] [Full Text] [PDF]

				C. E Murphy and P. T Rodgers Effects of Thiazolidinediones on Bone Loss and Fracture Ann. Pharmacother., December 1, 2007; 41(12): 2014 - 2018. [Abstract] [Full Text] [PDF]

				Z. Berberoglu, A. Gursoy, N. Bayraktar, A. C. Yazici, N. Bascil Tutuncu, and N. Guvener Demirag Rosiglitazone Decreases Serum Bone-Specific Alkaline Phosphatase Activity in Postmenopausal Diabetic Women J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3523 - 3530. [Abstract] [Full Text] [PDF]

				A. V. Schwartz and D. E. Sellmeyer Thiazolidinedione Therapy Gets Complicated: Is bone loss the price of improved insulin resistance? Diabetes Care, June 1, 2007; 30(6): 1670 - 1671. [Full Text] [PDF]

				Rosiglitazone May Reduce Bone Density Journal Watch (General), April 24, 2007; 2007(424): 4 - 4. [Full Text]

				A. V. Schwartz and D. E. Sellmeyer Thiazolidinediones: New Evidence of Bone Loss J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1232 - 1234. [Full Text] [PDF]